As we age, some cells stop dividing but stay alive. Scientists call these senescent cells. Some release chemical signals that encourage inflammation in nearby tissue. When this activity persists, it can contribute to damage. [1]
But senescence also has useful roles. Stopping damaged cells from dividing can help protect against cancer, and senescent cells can take part in tissue repair. That raises an interesting question: could researchers reduce their inflammatory signals while leaving the cells in place? [1]
A study in Nature explored this in cells grown in the laboratory and in older mice. An experimental compound reduced inflammatory signals, and treated mice improved on some measures of physical health. The findings open a possible route for future treatments, although benefits for people remain untested. [1]
How did the researchers turn down inflammation?
The researchers focused on mitochondria: small structures inside cells that help process nutrients and supply energy. They also influence which chemical signals a cell produces. [1]
In the cell experiments, inflammation depended on two things working together. Material leaking from damaged mitochondria acted as an alarm. Meanwhile, substances produced through the cell’s metabolism helped keep the instructions for making inflammatory signals accessible. [1]
The team targeted the second process with a compound called CTPI2. It blocks SLC25A1, a protein that transports a substance called citrate out of mitochondria. Interrupting that supply made it harder for the cell to maintain its inflammatory activity. [1]
The cells produced and released fewer inflammatory signals, collectively known as SASP. They still did not divide. This distinction matters: the experiment reduced one potentially harmful behaviour without showing that the cells had become young again. [1]
What improved in the mice?
Male and female mice started treatment at 19 months of age. Researchers randomly assigned them to receive CTPI2 or a comparison treatment without the compound, three times a week for three months. [1]
The treated mice had lower inflammatory signals in several tissues. They also did better on some tests of strength and frailty—measures used to assess physical weakness and declining function. Bone structure did not improve. The study did not test whether the mice lived longer. [1]
Could this help people?
We do not know yet. The researchers examined existing data from human tissues and found links between the transport protein and signs of cell ageing and inflammation. Nobody in that analysis received CTPI2, so it cannot tell us whether the compound would help people. [1]
The useful idea is that researchers may be able to reduce harmful signals from senescent cells while keeping them from dividing. Whether that approach preserves their protective roles needs further testing. [1]
Before this could become a treatment, other researchers would need to reproduce the results and investigate longer-term safety. Human trials would then need to show meaningful benefits, such as better physical function. For now, CTPI2 is an experimental research compound; this study provides no basis for using it to slow ageing in people.